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Traumatic brain injury (TBI) is a major health and socio-economic problem that affects
all societies. This condition results from the application of external physical strength to
the brain that leads to transitory or permanent structural and functional impairments.
Moreover, TBI is a risk factor for neurodegeneration and can e.g., increase the risk
for Parkinson’s disease (PD), a late-onset neurodegenerative disorder with loss of
dopaminergic neurons in substantia nigra. In this study, we wanted to explore the
possible development of PD-related pathology within the context of an experimental
model of TBI. Traumatic brain injury was induced in mice by controlled cortical impact.
At different time points behavioral tests (open field, elevated plus maze tests, and
Barnes maze) were performed: The animals were sacrificed 30 days after the impact
and the brains were processed for Western blot and immunohistochemical analyses.
Following TBI there was a significant decrease in expression of tyrosine hydroxylase
and dopamine transporter in the substantia nigra as well as significant behavioral
alterations. In addition, a strong increase in neuroinflammation was evident, as shown
by increased levels of cyclooxygenase-2 and inducible nitric oxide synthase as well as
IκB-α degradation and nuclear-κB translocation. Moreover, neurotrophic factors such
as brain-derived neurotrophic factor, neurotrophin-3, nerve growth factor, and glial cell
line-derived neurotrophic factor were decreased 30 days post-TBI. Interestingly, we
observed a significant accumulation of α-synuclein in microglia compared to astrocytes.
This study suggests that PD-related molecular events can be triggered upon TBI. The
biological mechanisms linking brain trauma and neurodegenerative diseases need to be
further investigated.
Keywords: chronic traumatic brain injury, Parkinson’s disease, α-synuclein, nuclear factor-κB, microglia,
astrocytes, neurotrophic factors, non-motor symptoms
INTRODUCTION
Traumatic brain injury (TBI) is described as an intracranial injury to the brain resulting from
an external force that can lead to transient or permanent impairment of cognitive, physical, and
psychosocial functions (Maas et al., 2008). Although TBI is basically considered an acute injury, the
accumulation of clinical and laboratory verification has recognized the chronic pathology of the
disease (Lozano et al., 2015). TBI is not a distinct event but a complex process (Masel and DeWitt,
2010) which causes structural and functional deficits due to both primary and secondary injury
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mechanisms (Davis, 2000). The primary injury results from
the immediate mechanical disruption of cerebral tissue (acute
stage) that occurs at the time of external force and includes
contusion and hemorrhage (Gaetz, 2004). Secondary injury
progresses over minutes to months after the primary damage
and is the consequence of cascades of molecular and cellular
events that lead to tissue damage, atrophy and brain cell
death (Marklund et al., 2006; Bramlett and Dietrich, 2007;
Lozano et al., 2015). TBI is closely related to the development
of chronic neuro-inflammation, sensory-motor, and cognitive
complications which appear some 5–6 years after the traumatic
event, and corresponds to∼30 days in the mouse (chronic stage)
(Ettenhofer and Abeles, 2009; Ozen and Fernandes, 2012; Acosta
et al., 2013; Kirkwood and Yeates, 2013).
Few studies have investigated the possibility that chronic
TBI causes secondary injury with pathophysiological changes
similar to those seen in neurodegenerative diseases such as
dementia pugilistica, Alzheimer disease (Saing et al., 2012) and
Parkinson’s disease (PD) (Saing et al., 2012; Acosta et al., 2013;
Xiong et al., 2013). Parkinson’s disease is a late-onset age-related
neurodegenerative disorder of unknown etiology, characterized
by a progressive loss of cathecolaminergic neurons, especially
dopaminergic neurons within the substantia nigra pars compacta
and the presence of α-syn-rich cytoplasmic neuronal inclusions
named Lewy bodies (Dauer and Przedborski, 2003; Brandt et al.,
2008). Alpha-synuclein (α-syn) is a 14-kDa synaptic protein with
a key role in PD progression (Maroteaux et al., 1988) and it
has a high propensity to misfold and aggregate as a response to
an increase in its concentration, post-translational modifications,
mutations, oxidative stress, pH, and metal ions (Hoyer et al.,
2002; Jomova et al., 2010; Oueslati et al., 2010).
Neuroinflammation plays a fundamental role in the
pathogenesis of TBI, involving cells of the innate immune system
such as microglia, astrocytes, pro-inflammatory cytokines, and
chemokines that interfere with the brain’s endogenous ability
to self-repair, thereby exacerbating neuronal cell death (Tajiri
et al., 2014). The transcription factor nuclear factor kappa B
(NF-κB) is a key modulator in inflammatory gene expression in
the nervous system (Grilli and Memo, 1999), which is activated
in response to inflammatory mediators and oxidative stress
(Baldwin, 1996). Brains from patients with dementia pugilistica
exhibit an abnormal accumulation of α-synuclein (α-syn) in
axonal swellings and dystrophic neurites, suggesting a potential
link between brain trauma, and the development of α-syn
pathology in PD (Newell et al., 1999). The mediators between
brain trauma and PD pathophysiology are unknown, but may
involve oxidative and/or nitrative stress (Mésenge et al., 1998).
Abbreviations: DAPI, 4′, 6′-diamidino-2-phenylindole; BDNF, Brain-derived
neurotrophic factor; CCI, Controlled cortical impact; Cox-2, Cyclooxygenase-2;
DAT, Dopamine transporter; EPM, Elevated plus-maze; GDNF, Glial cell line-
derived neurotrophic factor; GFAP, Glial fibrillary acidic protein; iNOS, Inducible
nitric oxide synthase expression; Iba1, Ionized calcium-binding adapter molecule
1; NeuN, Neuronal nuclear antigen; NT3, Neurotrophin-3; IκBα, Nuclear factor
of kappa light polypeptide gene enhancer in B-cells inhibitor α; NF-κB, Nuclear
factor -κB; OF, Open field test; PD, Parkinson’s disease; PBS, Phosphate-buffered
saline; SEM, Standard error of the mean; SN, Substantia nigra; TBI, Traumatic
brain injury; TH, Tyrosine hydroxylase; α-syn, α-synuclein.
The present study was carried out to better understand
the molecular mechanisms that associate the long-term
consequences of TBI with the development of parkinsonism,




Male CD1 mice (25–30 g, Harlan, Milan, Italy), aged between
10 and 12 weeks, were used for all studies. Mice were housed
five per cage and maintained under a 12:12 h light/dark cycle
at 21 ± 1◦C and 50 ± 5% humidity. Standard laboratory diet
and tap water were available ad libitum. The University of
Messina Review Board for the care of animals approved the
study. Animal care was in compliance with Italian regulations on
protection of animals used for experimental and other scientific
purposes (Ministerial Decree 16192) as well as with the Council
Regulation (EEC) (Official Journal of the European Union L
358/1 12/18/1986).
Controlled Cortical Impact (CCI)
Experimental TBI
TBI was induced in mice by a controlled cortical impactor (CCI)
as previously described (Campolo et al., 2014). A craniotomy
was induced in the right hemisphere, with a Micro motor
hand piece and drill (UGO Basile SRL, Comerio Varese, Italy),
encompassing bregma and lambda, and among the sagittal suture
and the coronal ridge. The consequential bone flap was removed
and the craniotomy enlarged additionally with cranial rongeurs
(New Adalat Garh, Roras Road, Pakistan). A cortical contusion
was made on the exposed cortex using the controlled impactor
device Impact OneTM Stereotaxic impactor for CCI (Leica,
Milan, Italy). Concisely, the impacting shaft was extended, and
the impact tip was lowered over the craniotomy site until it
touched the dura mater. Subsequently, the rod was retracted,
and the impact tip was advanced farther to produce a brain
injury of moderate severity for mice (tip diameter: 4mm;
cortical contusion depth: 3mm; impact velocity: 1.5m/sec).
Instantaneously after injury, the skin incision was secure with
nylon sutures, and 2% lidocaine jelly was spread to the lesion site
to reduce pain.
Experimental Groups
Mice were randomly allocated into the following groups:
Sham group: mice were subjected to equal surgical procedures
except for TBI and were kept under anesthesia for the duration
of the experiment (n= 10).
TBI group: mice were subjected to CCI (n= 10).
Mice were sacrificed 30 days after TBI, the brains removed and
the midbrain dissected out for study. Immunohistochemical
localization of PD markers (TH, α-syn, and dopamine
transporter (DAT) was assessed. Western blot was used to
determine the translocation of NF-κB and degradation of IκBα.
In addition, over the 30-day experimental period behavioral
changes at 1, 7, 14, and 30 days were evaluated.
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Behavioral Testing
All animals were subjected to the same battery of behavioral
tests at 1, 7, 14, and 30 days post-CCI. All behavioral testing
was conducted during the light cycle phase and in enclosed
behavior rooms (50–55 dB ambient noise) within the housing
room. The mice were placed in behavior rooms 5min for 2 days
for acclimation prior to the onset of behavioral testing.
The behavioral tests were conducted by three different reliable
expert observers blinded to the injury status of the animals. Tests
are described below:
Open field test (OF): Locomotor activity and anxiety-like
behavior were monitored for 5 min using the open field test,
a white Plexiglas box 50 × 50 cm with its floor divided into
16 squares. Four squares were defined as the center and 12
squares along the walls as the periphery. Each mouse was
gently placed in the center of the box and activity was scored
as a line crossing when a mouse removed all four paws from
one square and entered another. Before each trial, the chamber
was cleaned with water containing a detergent. The animals’
behavior was videotaped. The line crossings and the time spent
in the center were counted and scored (Prut and Belzung,
2003).
Elevated pluz-maze (EPM): The EPM test was used to measure
anxiety-like behavior, as described previously (Pellow et al.,
1985). The EPM apparatus consisted in two open arms (30
× 5 × 0.25 cm) and two enclosed arms (30 × 5 × 15 cm)
extended from a common central platform (5 × 5 cm) and
the entire apparatus was elevated by a single central support
to a height of 60 cm above floor level. The behavioral model
was based on rodents’ aversion of open spaces that leads to
thigmotaxis. Anxiety reduction was indicated by an increase in
the proportion of time spent in the open arms and an increase
in the proportion of entries into the open arms. The total
numbers of arm entries and number of closed-arm entries
were used as measures of general activity.
Barnes maze: The Barnes maze is a less stressful alternative
than the Morris water maze, and is a validated test often
used to assess spatial learning and memory in rodents. The
test consists of a circular surface with up to 20 circular
holes around its circumference. Under one of the holes is an
escape box which can be reached by the rodent through the
corresponding hole on the table top. The model was based
on rodents’ aversion of open spaces, which motivates the test
subject to seek shelter in the escape box. The performance was
measured by number of errors the rodent makes and the rate
of decline in the number of errors per trial was calculated to
represent a learning curve (Barnes, 1979).
Western Blot Analyses
Cytosolic and nuclear extracts were prepared as previously
described (Esposito et al., 2012), with slight modifications.
The ipsilateral hemisphere from each mouse after injury was
collected and suspended in Buffer A containing protease
inhibitors, homogenized for 2min, then centrifuged at
1000× g for 10min at 4◦C. Supernatants contained the
cytosolic fraction. The pellets, containing enriched nuclei,
were resuspended in Buffer B containing 1% Triton X-100,
150mM NaCl, 10mM Tris-HCl pH 7.4, 1mM, ethylene glycol
tetra-acetic acid, 1mM, ethylenediaminetetraacetic acid, 0.2
mM phenylmethanesulfonylfluoride and protease inhibitors.
After centrifugation for 30min at 15,000× g at 4◦C, the
supernatants containing nuclear proteins were stored at −80◦C
for further analysis. The expression of inducible nitric oxide
synthase (iNOS), cyclooxygenase (COX)-2 and IκBα were
quantified in cytosolic fractions. NF-κBp65 was quantified
in nuclear fractions collected 30 days after TBI. The filters
were probed with specific antibodies for iNOS (1:1000; BD
Biosciences, Milan, Italy), COX-2 (1:1000; Cayman Chemicals,
Tallinn Estonia), glial fibrillary acidic protein (GFAP) (1:2000;
Santa Cruz Biotechnology, Heidelberg, Germany), NFκBp65
(1:500; Santa Cruz Biotechnology) and IκBα (1:500; Santa Cruz
Biotechnology) at 4◦C overnight in 1 × phosphate-buffered
saline (PBS), 5% (w/v), non-fat dried milk and 0.1% Tween-20.
Membranes were incubated with peroxidase-conjugated bovine
anti-mouse IgG secondary antibody or peroxidase-conjugated
goat anti-rabbit IgG (1:2000; Jackson ImmunoResearch, West
Grove, PA, USA) for 1 h at room temperature. To ascertain
that blots were loaded with equal amounts of protein, then they
were incubated in the presence of antibodies against β-actin
or lamin A/C (1:5000; Santa Cruz Biotechnology). The signals
were detected with enhanced a chemiluminescence detection
system reagent according to the manufacturer’s instructions
(Super Signal West Pico Chemiluminescent Substrate, Pierce
Thermo Scientific, Rockford, IL. USA). Relative expression of
bands for IκBα (approximately 37 kDa), NF-κB (approximately
65 kDa), iNOS (approximately 130 kDa), COX-2 (approximately
72 kDa) and GFAP (approximately 55 kDa) were imported to
analysis software (Image Quant TL, v2003) and standardized
to β-actin and lamin A/C levels. The relative expression of the
protein bands was calculated by densitometry with Bio-Rad
ChemiDocTM XRS+software. Molecular weight standards (10–
250 kDa) were used to define molecular weight positions, and as
reference concentrations for each protein.
Immunofluorescence
After deparaffinization and rehydration, detection of TH, α-syn,
NeuN, GFAP, Iba1, and neurotrophin-3 (NT-3) was carried out
after boiling the tissue sections in 0.1M citrate buffer for 1 min.
Non-specific adsorption was minimized by incubating in 2%
(vol/vol) normal goat serum in PBS for 20min. Sections were
incubated with one of the following primary antibodies: mouse
monoclonal anti-TH (1:100, Millipore), mouse monoclonal anti-
α-syn (1:100, Santa Cruz Biotechnology), rabbit polyclonal anti-
GFAP (1:100, Santa Cruz Biotechnology), rabbit polyclonal anti-
Iba1 (1:100, Santa Cruz Biotechnology), rabbit polyclonal anti-
NeuN (1:100, Santa Cruz Biotechnology) or rabbit polyclonal
anti-NT3 (1:100, Millipore) in a humidified oxygen and nitrogen
chamber overnight at 37◦C. Sections were then incubated with
secondary antibody: fluorescein isothiocyanate-conjugated anti-
mouse Alexa Fluor-488 (1:2000, Molecular Probes, Monza, Italy)
or Texas Red-conjugated anti-rabbit Alexa Fluor-594 (1:1000,
Molecular Probes) for 1 h at 37◦C. For nuclear staining, 2 µg/ml
4′, 6′-diamidino-2-phenylindole (DAPI; Hoechst, Frankfurt,
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Germany) in PBS was added. Sections were observed at 20×
and 40x magnification using a Leica DM2000 microscope (Leica,
Milan, Italy). TH+, a-syn+, NeuN+, GFAP+, Iba1+, and NT-
3+cells were counted stereologically on sections cut at a 40µm
thickness and every 4th section was counted using a grid of
100 × 100µm (Mallajosyula et al., 2008). Optical sections
of fluorescence specimens were obtained using a HeNe laser
(543 nm), an ultraviolet laser (361–365 nm) and an argon laser
(458 nm) at a one-mi, 2 s scanning speed with up to eight
averages; 1.5µm sections were obtained using a pinhole of 250.
Examining the most brightly labeled pixels and applying settings
that allowed clear visualization of structural details, while keeping
the highest pixel intensities close to 200, established contrast and
brightness. The same settings were used for all images obtained
from the other samples that had been processed in parallel.
Digital images were cropped and figure montages prepared using
Adobe Photoshop 7.0 (Adobe Systems; Palo Alto, California,
United States). The co-localization of images was examined with
Image J software (National Institutes of Health) as described
previously (Zhou et al., 2011).
Immunohistochemistry
Brain tissues were fixed in 10% (w/v) buffered formaldehyde
30 days after TBI, and 7-µm sections were prepared from
paraffin-embedded tissues. After deparaffinization, endogenous
peroxidase was quenched with 0.3% H2O2 in 60% methanol
for 30min. The sections were permeabilized with 0.1% Triton
X-100 (Sigma-Aldrich, Milan, Italy) in PBS (pH 7.4) for 20
min. Non-specific adsorption was minimized by incubating
the section in 2% normal goat serum in PBS for 20min.
Endogenous biotin- or avidin-binding sites were blocked
by sequential incubation for 15min with avidin and biotin.
The sections were then incubated overnight with one of the
following primary antibodies diluted in PBS: anti-TH (1:500,
Millipore-monoclonal or polyclonal), anti-DAT (1:500, Santa
Cruz Biotechnology polyclonal), polyclonal anti-glial cell
line-derived neurotrophic factor (GDNF) (1:500, Santa Cruz
Biotechnology), polyclonal anti-brain-derived neurotrophic
factor (BDNF) (1:500, Santa Cruz Biotechnology), anti-α-syn
(1:250, Santa Cruz Biotechnology-polyclonal), and anti-NT-
3 (1:500, Millipore-polyclonal). The immunohistochemical
pictures were collected by Zeiss microscope using Axio Vision
software. For graphic representation of densitometric analyses,
we measured the intensity of positive staining (brown staining)
by computer-assisted color image analysis (Leica QWin V3,
UK). The percentage area of immunoreactivity (determined
by the number of positive pixels) was expressed as percent of
total tissue area (red staining). Photomicrographs were assessed
densitometrically with Optilab software (Graftek, Mirmande,
France) on a MacBook Pro computer (Apple, Cupertino, CA,
USA). Analysis was carried out by assigning quantitative different
criteria for staining intensity as described by Ding et al. (2012),
which included assignment of staining intensity using a scale of
0–10 (with 0 indicating a lack of brown immunoreactivity and 10
reflecting intense dark brown staining) by three different reliable
expert observers. The mean was then calculated and results
converted into grades: a score of 1–3 was assigned “+,” 4–6 was
“++,” more than 7 was “+ + +”(Ding et al., 2012). Scores from
all sections of each brain were averaged to give a final score for
each mouse. All histological studies were performed in a blinded
fashion.
Tissue Processing and Histology
An experienced histopathologist evaluated sagittal sections of 5-
µm thickness from the perilesional brain area of each animal.
Histopathologic changes of the gray matter were scored on a six-
point scale (Kawai and Akira, 2007) as described by Campolo
et al. (2014). Scores from all sections of each brain were averaged
to give a final score for each mouse. All histological studies were
performed in a blinded fashion.
Statistical Analysis
All values in the figures and text are expressed as mean ±
standard error of the mean (SEM) of N observations. For in
vivo studies N represents the number of animals. In those
experiments involving histology or immunohistochemistry, the
figures shown are representative of at least three experiments
performed on different days. Results were analyzed by one-way
ANOVA followed by a Bonferroni post-hoc test for multiple
comparisons. A F-value was shown, p-value of less than 0.05 was
considered significant.
RESULTS
Changes of PD Markers in the SNc after
Chronic TBI
To examine if chronic TBI can modify PD-like markers, brain
sections from control and TBI mice 30 days after surgery were
stained with dopaminergic-specific markers (TH and DAT) and
α-syn. Midbrain expression of TH-positive neurons and DAT
was significantly decreased 30 days after TBI (Figures 1A,B,
respectively, see densitometric analysis, Figure 1D; F = 3 for
TH and for DAT). Western blot analysis confirmed a significant
reduction of TH and DAT protein expression (Figure 1A1, P <
0.005; and Figure 1B1, respectively, P < 0.05; F = 1.111 for TH
and 4.88 for DAT). In contrast, chronic TBI resulted in a visible
increase in α-syn staining compared to control group (Figure 1C,
see densitometric analysis, Figure 1D, F = 3) and protein as
shown byWestern blot analysis (Figure 1C1 P< 0.01; F= 0.078).
To confirm these data, TH and α-syn were double-
stained with antibodies against the neuronal marker NeuN,
in the midbrain. Thirty days after TBI there was an evident
accumulation of α-syn in neurons compared with sham mice
(Figure 2B, see corresponding cell count analysis; F = 0.428).
On the other hand, TH-positive neuron counts were significantly
decreased (Figure 2A, see corresponding cell count analysis; F =
7). Also, to evaluate the α-syn accumulation specifically in the
dopaminergic neurons we assessed a double staining between TH
and α-syn (Figure 2C). We noticed a basal level of α-syn into the
dopaminergic neurons TH-positive in sham group while 30 days
after TBI there was an increasing accumulation of α-syn in the
TH positive neurons (Figure 2C).
Frontiers in Neuroscience | www.frontiersin.org 4 October 2016 | Volume 10 | Article 458
Impellizzeri et al. Chronic TBI Induces Parkinson’s Disease
FIGURE 1 | Effect of chronic TBI on Parkinsonian markers. Midbrain was stained with antibodies against tyrosine hydroxylase (A), dopamine transporter (B) and
α–synuclein (C). Immunohistochemical analysis of midbrain obtained from mice subjected to TBI revealed a positive staining for TH, DAT, and α-syn [TBI panels TBI
(A–C) respectively; see densitometric analysis, D] compared with sham-operated mice [Sham panels TBI (A–C) respectively; see densitometric analysis, D]. Data are
expressed as a percentage of total tissue area and are means ± SE of 5 mice/group. **P < 0.005 vs. Sham; *P < 0.05 vs. sham (Student’s t-test). Western blot
analysis confirmed our data (A1–C1 respectively). Each data are expressed as Mean ± SEM from N = 5 mice/group. *P < 0.01 vs. sham, **P < 0.005 vs. sham.
Microglia, but not Astrocytes in the SNc
Regulate α-syn Expression after Chronic
TBI
To evaluate microglia involvement and its correlation with
PD markers, the midbrain was double-stained with antibodies
against Iba1 (red; Figure 3A) and α-syn (green; Figure 3A).
Microglial cells (Iba1-+cells) visibly expressed α-syn-positive
staining in chronic TBI tissue (Figure 3A) compared to sham.
Further, there was a clear co-localization of α-syn and Iba1 in the
TBI samples (merged, Figure 3A- see cell count analysis A1; F =
0.428).
To analyze the activation of astrocytes and its involvement
in PD, contused brain tissue at the collision site 30 days after
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FIGURE 2 | Effects of chronic TBI on Tyrosine hydroxylase (TH) and α-synuclein expression in NeuN positive cells. Midbrain was double-stained with
antibodies against NeuN (red), TH (green) (A), or α-syn (red) (B). The red spots indicate the co-localizations (merged) indicated by yellow arrows. TH-positive neurons
were significantly reduced after chronic TBI (TBI merged A). Midbrain sections revealed increased α-syn positive neurons 30 days after TBI (TBI merged B). Moreover,
midbrain sections showed a marked α-syn accumulation in TH+ cell (TBI merged C). Scale bar = 50 and 20 µm (particle). Data are expressed as Mean ± SEM from
N = 5 mice/group. Counting of colocalized cell confirmed our data. The co-localization of image was analyzed with image J software. *P < 0.05 vs. sham (Student’s
t-test), **P < 0.005.
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FIGURE 3 | Effect of chronic TBI on α-synuclein expression in ionized calcium binding adaptor molecule 1 (Iba1) and glial fibrillary acidic protein
(GFAP) positive cells. Midbrain sections wer double-stained with antibodies against Iba1 (red) or GFAP (red) and α-syn (green). The red spots indicate the
co-localizations (merged) indicated by yellow arrows. There were increased microglia cells (Iba1+cells) in TBI mice (A) as compared to the control group (Sham A).
α-syn positive neurons were significantly increased in microglia after chronic TBI (TBI merged A). Considerable astrogliosis (GFAP+cells) was present in TBI panels (B).
α-syn positive neurons did not show any significant immunoreactivity in astrocytes after TBI (TBI merged B). Scale bar = 50 and 20 µm (particle). Each data are
expressed as Mean ± SEM from N = 5 mice/group. Counting of colocalized cell confirmed our data. The co-localization of image was analyzed with image J
software. *P < 0.05.
injury was double-stained with for GFAP (red; Figure 3B) and
α-syn (green; Figure 3B) or TH (green; Figure 4). Midbrain
sections showed an increased astrogliosis (GFAP+ cells) in TBI
panels (Figures 3B, 4). Furthermore, there was a non-significant
co-localization of both α-syn and TH in GFAP+ cells after
chronic TBI [merged, Figures 3B, 4, respectively- see cell count
analysis in Figures 3B1 (F = 1) and Figure 4A, respectively
(F = 1)].
Chronic TBI Induces a Significant
Neuroinflammatory Response Regulated
by NF-κB
To investigate the cellular substrate(s) that link PD with chronic
TBI, Western blot analysis was assessed in midbrain tissue 30
days post-TBI, using IκBα- and NF-κB- specific antibodies.
There was a basal expression of IκBα in sham mice (Figure 5A,
see densitometry analysis (P < 0.005), while IκBα expression
was considerably reduced in mice subjected to chronic TBI
(Figure 5A, see densitometry analysis, P < 0.005; F = 1.087).
Moreover, p65 subunit translocation was increased in nuclear
brain homogenates after TBI, compared with sham (Figure 5B,
see densitometry analysis P < 0.01; F = 0.0195). Translocation of
NF-κB is a critical phase in the coupling of extracellular stimuli
to the transcriptional stimulation of specific pro-inflammatory
target genes such as iNOS and COX-2. To evaluate the role of
nitric oxide in TBI, iNOS expression was evaluated by Western
blot analysis. At 30 days post-TBI there was a significant increase
in iNOS expression in midbrain of TBI mice (Figure 5C, see
densitometry analysis, P < 0.005, F = 0.0312). COX-2 expression
was also stimulated by TBI compared to sham (Figure 5D, see
densitometry analysis, P < 0.001, F = 0.0019).
Chronic TBI Reduces Neurotrophic Factor
Expression Levels
To test whether chronic TBI modulates PD via regulation
of neurotrophic factors, we used immunohistochemistry to
examine BDNF, GDNF, and NT-3 levels in the midbrain. Thirty
days post-trauma there was a reduction in immunostaining for
all three neurotrophic proteins (Figures 6A–C, respectively,
see densitometric analysis, Figure 6D; F = 3 for BDNF and
GDNF, and F = 1.0002 for NT-3) in comparison to sham
animals. Moreover, Western blot analysis confirmed these
observations (Figures 6A1–C1, respectively, see densitometric
analysis, Figure 6D: P < 0.005, P < 0.001, and P < 0.05,
respectively; and F = 2.156, 1.318, 9.30 for BDNF, GDNF,
and NT-3).
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FIGURE 4 | Effect of chronic TBI on Tyrosine hydroxylase (TH) expression in glial fibrillary acidic protein (GFAP) positive cells. Midbrain tissues were
double-stained with antibodies against GFAP (red) and TH (green). The red spots indicate the co-localizations (merged) indicated by yellow arrows. Midbrain sections
revealed increased astrogliosis (GFAP+ cells) in TBI panels. TH positive neurons were significantly reduced after TBI (TBI merged panel). Scale bar = 50 and 20µm
(particle). Each data are expressed as Mean ± SEM from N = 5 mice/group. Counting of colocalized cell confirmed our data. The co-localization of image was
analyzed with image J software.
Chronic TBI Induces Depression- and
Anxiety-Like Behaviors in the Mouse
To examine anxiety-like behavior and locomotor function, mice
subjected to chronic TBI were compared to sham mice at 1, 7,
14, and 30 days on several behavioral tests, including the open
field test, EPM, and Barnes maze. Mice were tested in the EPM
at all time points, TBI mice spent notably less time in the open
arms as compared to sham animals (Figure 7A, see densitometric
analysis, Figure 7F, F = 1.333 at 1 days, F = 1 at 3 days, F = 1
at 7 days, F = 4 at 30 days). The anxiety-like phenotype induced
by the lesion was confirmed in the open field test (Figures 7B,B1,
see densitometric analysis, Figure 7F; ∗P < 0.05 and ∗∗P < 0.005;
Figure 7B, F = 1.750 at 1 days, F = 4 at 3 days, F = 3 at 7 days, F
= 3 at 30 days; Figure 7B1, F = 1.531 at 1 d, F = 3.226 at 3 days,
F = 4 at 7 days, F = 4 at 30 days). Chronic TBI mice showed
a pronounced increase in thigmotaxis, seen as the tendency to
remain close to the wall (Simon et al., 1994), when compared to
shammice, as specified by less time spent in the center of the open
field (Figure 7B, ∗P< 0.05 and ∗∗P< 0.005 vs. sham) and shorter
distance covered in the center of the open field (Figure 7B1, P
< 0.05 vs. sham). Spatial learning and memory were assessed in
TBI mice using the Barnes maze. In this test, sham mice quickly
learned to escape the open field and reach the black escape box,
as revealed by the rapid decline in escape latency. In contrast,
there was a statistically significant decrease in spatial learning
induced by TBI for all time points, with an increase in escape
latency and mean number of errors (Figures 7C,C1, respectively,
see densitometric analysis, Figure 7F, ∗∗∗P < 0.001 vs. sham;
Figure 7C) F = 12 at 1 days, F = 2.583 at 3 days, F = 7 at 7 days,
F = 1.714 at 30 days): Figure C1) F = 1 at 1 days, F = 1 at 3 days,
F = 2.333 at 7 days, F = 4 at 30 days).
Behavioral tests showed the degree of severity in our TBI
model 30 days post-trauma. Using hematoxylin and eosin
staining we failed to detect any frank cell loss or alteration
of tissue morphology in the midbrain either 24 or 48 h after
TBI compared to sham groups (Figures 7D,E, respectively,
see densitometric analysis, Figure 7F, see histological score
∗P < 0.05).
DISCUSSION
A strong association of TBI with an increased risk of PD has
been documented (Bower et al., 2003; Goldman et al., 2006).
The development of animal models of TBI that validate many
fundamental pathophysiological processes related to PD has been
an important advance in this field (Uryu et al., 2003; Xiong et al.,
2013). Among themanymechanisms associated in PD pathology,
α-syn accumulation coupled with TBI appears to synergistically
impact on PD symptoms (Shahaduzzaman et al., 2013; Ulusoy
and Di Monte, 2013). In the present study we demonstrate
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FIGURE 5 | Effects of chronic TBI on Nuclear factor κB (NF-κB) pathway and pro-inflammatory enzymes. Degradation of IκBα was significantly increased 30
days after TBI (A). Also, chronic TBI resulted in enhancednuclear translocation of p65 (B). A significant increase in inducible nitric oxide synthase (iNOS) and
cyclooxygenase (COX)-2 (C,D, respectively) was observed in the midbrain from TBI mice compared with the Sham mice (C,D, respectively). Data show one
representative blot from three independent experiments with similar results. Data are expressed as Mean ± SEM from N = 5 mice/group. * P < 0.01 vs. sham, **P <
0.005 vs. sham,***P < 0.005 vs. sham. (Student’s t-test).
that already 30 days after TBI PD-like markers are significantly
up regulated. In addition, midbrain tissue of chronic TBI mice
displayed a remarkable decrease in the immunohistochemical
expression of dopaminergic markers, along with an evident
accumulation of α-syn in neurons.
Inflammation plays an important role in PD (Engler
et al., 2009). Dopaminergic neurons are highly susceptible to
inflammation and oxidative damage and neuroinflammation
mediated by glial cells has attracted much attention. Previous
studies revealed abnormalities in astrocytes and microglia in PD
patients, suggesting involvement of these two cell populations in
the development of early stage PD (Rappold and Tieu, 2010).
TBI is reported to lead to accumulation of α-syn in microglial
cells and astrocytes11, leading to propagation of damage to
neurons that perpetuates neurodegeneration. Our results show a
significant accumulation of α-syn in microglia but not astrocytes,
which could represent an important link between TBI and PD.
In addition, microglial infiltration into the substantia nigra has
been suggested to alter the inflammatory environment, and
promote the buildup of α-syn (Acosta et al., 2015). In some
studies microglia have been shown to activate NF-κB, leading to
dopamine neuron degeneration, possibly through apoptotic cell
death (Phani et al., 2012).
NF-κB is a cardinal transcriptional regulator of inflammation
and apoptosis, neuronal cell survival, and signaling involved
in brain damage. NF-κB activation may persist for at least
1 year following cortical injury, suggesting that chronic NF-
κB activation may play a role in long-term inflammatory
mechanism following brain trauma (Nonaka et al., 1999). In
fact, our data show a clear and significant expression of NF-
κB 30 days after TBI. In line with this, there was a significant
increase in the degradation of cytoplasmic IKB. Further, NF-
κB activation in the midbrain was accompanied by increased
transcription of the inflammatory markers COX-2 and iNOS.
The latter may result in production of high levels of nitric
oxide and superoxide radicals, which are neurotoxic. COX-2,
which generates prostaglandins, represents a potential hazard
for dopamine neurons. In fact, increased COX-2 expression was
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FIGURE 6 | Effect of chronic TBI on Neurotrophic factors. By immunohistochemical analysis, a basal level of BDNF (A) GDNF (B) and NT-3 (C) positive staining
was detected in midbrain samples from sham-operated mice (sham panels A–C respectively; see densitometric analysis, D). BDNF and GDNF and NT-3 expression
was significantly reduced in midbrain samples from TBI mice (TBI panels A–C respectively; see densitometric analysis, D). Data are expressed as a percentage of total
tissue area and are means ± SE of 5 mice/group. **P < 0.005 vs. Sham; *P < 0.05 vs. sham (Student’s t-test). Western blot analysis confirmed our data showing a
significant decrease of neurotrophic factor following TBI (A1–C1 respectively, see correspond densitometric analysis). Each data are expressed as Mean ± SEM from
N = 5 mice/group. **P < 0.005 vs. sham; *P < 0.05 vs. sham (Student’s t-test).
localized to the substantia nigra pars compacta in post-mortem
brains of PD patients (Przedborski, 2007). We hypothesize
that NF-κB activity in the midbrain could play a key role in
determining inflammatory processes in the lesioned nigrostriatal
pathway, which consequently influence the neurodegenerative
outcome.
Neurons in the substantia nigra show up-regulated
dopaminergic markers in response to increases in BDNF,
GDNF, and NT-3 (Peterson and Nutt, 2008). BDNF elevation
has been associated to better performance into the motor cortex
(Zhao et al., 2016). GDNF has been linked to the survival of
dopaminergic cells in the substantia nigra through increases
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FIGURE 7 | Effect of chronic TBI on anxiety-like behaviors. The degree of non-motor impairment was assessed in a blinded manner at different time points
(1,7,14, and 30d) by elevated plus maze (EPT), open field (OF), and Barnes maze. EPM tests showed that TBI animals spent less time exploring the open arms and
head dipping than Sham animals (A). No significant differences in rearing or grooming were observed. OF tests showed that TBI mice traveled significantly shorter
distances and didn’t stay in the center area for longer (B,B1). Barnes maze revealed a decrease of spatial learning induced by TBI in all time point increasing the
latency for escape (C) and the mean number errors (C1) Data are means ± SE of 10 mice/group. *P < 0.05 vs. sham; **P < 0.005; ***P < 0.001 vs. sham (ANOVA
and Bonferroni test). H&E staining: (D–E). As compared with sham groups at 24 and 48 h (D,E respectively, see histological score F), after TBI wasn’t shown a
significant alteration of tissue morphology (D,E respectively, see histological score F) in the midbrain. Each data are expressed as Mean ± SEM from N = 5 Mice for
each group. Scale bar = 50 and 20µm (higher magnification).
in synaptic excitability (Bourque and Trudeau, 2000) and the
inhibition of apoptosis (Burke et al., 1998). BDNF, NT-3, and
GDNF, by binding to their respective high-affinity receptors
stimulate the survival and morphological differentiation of
midbrain dopaminergic neurons and increase dopamine uptake
(Baquet et al., 2005; von Bohlen und Halbach et al., 2005;
Grandoso et al., 2007; Stahl et al., 2011) Interestingly, our study
indicates a significant reduction in expression of BDNF, GDNF,
and NT-3 in the midbrain 30 days after TBI.
Parkinson’s disease does not only feature motor symptoms,
but also non-motor symptoms which can lead to cognitive
and psychiatric disturbances (Bonito-Oliva et al., 2014). The
depressive-like phenotype observed in our TBI-PD-induced
mouse model was paralleled by increased thigmotaxis and
reduced time spent in the open arms of the EPM, two standard
behavioral parameters of anxiety. These data are in agreement
with the frequent co-morbidity between anxiety and depression
observed in PD patients (Menza et al., 1993) and with a
number of observations in experimental models. Also, human
studies comparing neurobehavioral outcomes after TBI suggest
that cognitive and emotional impairments increase with injury
severity (Washington et al., 2012). Little is known about the
mechanistic role, direct or indirect, of the substantia nigra
on learning processes, and our Barnes maze test in chronic
TBI mice could reveal early dysfunction within the substantia
nigra (Li et al., 2013) or inability of the mice to effectively
utilize a search strategy. Furthermore, our findings demonstrate
that acute-to-chronic TBI could cause long-term deficits in
cognitive function that accompanies gradual lesion expansion
and continuing neurodegeneration evolving in PD.
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The present observations provide the first demonstration that
a cortical lesion can expand to the midbrain and culminate in the
expression of PD-like elements 30 days post-trauma. Specifically,
our study indicates specific cellular mechanisms that may link
chronic TBI and PD, in particular neuroinflammatory reactions
via the NF-κB pathway. Moreover, microglia appear to occupy a
prominent position as a link between TBI and the development
of PD-like pathology with aberrant α-syn accumulation, which
could play an important role in the neurodegenerative process.
In terms of the PD-related non-motor symptoms, chronic TBI
enhanced anxiety-like behavior and spatial learning. Based on
previous findings (DeKosky et al., 2013), our study also suggests
that such PD-like pathology and symptoms could represent an
etiology for other neurodegenerative diseases such as chronic
traumatic encephalopathy (dementia pugilistica). Although there
are limitations and challenges with animal models for mild TBI,
these should still be relevant for the study of behavioral sequelae
of single and repetitive mild TBI and how they relate to the
numerous complex histopathological pathways. For example,
the safety, and efficacy identified in animal studies may not
generally translate to human trials, since one cannot exclude
the possibility that some residual unmeasured confounders exist
(e.g., a behavior thatmay lead a person to bemore likely to sustain
a TBI and/or that may also be an independent risk factor for
PD). Also, this study is unable to provide information about the
neuro-functional assessment of chronic TBI.
Regardless of its limitations, this study has investigated
an under-appreciated biological mechanism that indicates a
causal relationship between brain injury and neurodegenerative
disease; In particular, our findings suggest that sustained
neuroinflammatory processes following a single moderate TBI
can lead to a PD-like pathophysiology in the midbrain.
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